Active Stocks
Wed May 22 2024 15:59:56
  1. Tata Steel share price
  2. 173.30 -0.57%
  1. ITC share price
  2. 439.75 1.10%
  1. State Bank Of India share price
  2. 819.30 -1.35%
  1. NTPC share price
  2. 373.40 0.40%
  1. Kotak Mahindra Bank share price
  2. 1,700.40 0.19%
Business News/ Companies / News/  Cipla, Roche launch covid-19 antibody cocktail at 59,750 per dose
BackBack

Cipla, Roche launch covid-19 antibody cocktail at ₹59,750 per dose

An antibody cocktail is a mixture of two or more unique biological drugs that act like human antibodies in the immune system and help fight off infection

Roche will import the antibody cocktail, developed by Regeneron, which will then be marketed and distributed in India through a strategic partnership with Cipla (REUTERS)Premium
Roche will import the antibody cocktail, developed by Regeneron, which will then be marketed and distributed in India through a strategic partnership with Cipla (REUTERS)

NEW DELHI:Swiss pharmaceutical firm Roche Holding AG and Cipla Ltd began selling on Monday a covid-19 antibody drug cocktail to treat non-hospitalized patients who face high risks of their infections turning severe.

The drug, which has been developed by New York-based Regeneron Pharmaceuticals Inc., comprises of two antibodies casirivimab and imdevimab. An antibody cocktail is a mix of two or more unique biological drugs that act like human antibodies to help fight off infection.

Roche Pharma India will import the cocktail, which will be marketed and distributed through a strategic partnership with Cipla.

Cipla will sell the two-dose pack at 119,500, the two companies said in a joint statement. The second batch will be made available by the middle of June.

“We are optimistic that the availability of antibody cocktail in India can help in minimizing hospitalization, ease the burden on healthcare systems and play a key role in treatment of high-risk patients before their condition worsens," V. Simpson Emmanuel, managing director and chief executive officer of Roche Pharma India, said in the statement.

In total, the antibody drug cocktail can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India can treat two patients, Roche and Cipla said.

The launch of the cocktail follows an emergency authorisation from the Drugs Controller General of India earlier this month.

You are on Mint! India's #1 news destination (Source: Press Gazette). To learn more about our business coverage and market insights Click Here!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 24 May 2021, 01:42 PM IST
Next Story footLogo
Recommended For You